Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD);Guía de práctica clínica sobre el manejo del paciente con enformedad por reflujo gastroesofágico (ERGE)

Gastroenterologia y Hepatologia

Volumn 25, Issue 2, 2002, Pages 85-110

  Marzo, M ^a   Alonso, P ^a   Bonfill, X ^a   Fernandez M ^a   Fernandez J ^b   Martinez, G ^b   Mearin F ^c   Mascort, J J ^b   Pique J M ^c   Ponce, J ^c   Saez M ^b  

^a Centro Cochrane Iberoamericano   (Spain)

^b Grupo de Seguridad del Paciente de la Sociedad Española de Medicina de Familia y Comunitaria semFYC   (Spain)

^c Oncology Group Asociaciõn Española de Gastroenterología   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALGINIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTACID AGENT; BARBITURIC ACID DERIVATIVE; CALCIUM ANTAGONIST; CIMETIDINE; DIAZEPAM; DOPAMINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MORPHINE DERIVATIVE; NITRATE; NIZATIDINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PROGESTERONE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; ROXATIDINE; SECRETIN; STOMACH SECRETION INHIBITOR; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG;

CLINICAL PRACTICE; CYTOPENIA; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; GYNECOMASTIA; HUMAN; LIVER TOXICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR;

EID: 0036326776     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5705(02)70245-8     Document Type: Article

References (123)

1. The prevalance of symptoms sugestive of esophageal disorders
2. Prevalance and clinical spectrum of gastroesophageal reflux: A population based study in Olmsted County, Minnesota
3. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
4. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori
5. Quality of life in patients with upper gastrointestinal symptoms: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
6. The impact of gastroesophageal reflux disease on health-related quality of life
7. An evidence-based appraisal of reflux disease management - The Genval Workshop Report
8. Epidemiology and natural history of reflux disease
9. Diagnostic evaluation in gastroesophageal reflux disease
10. Diagnosis of reflux disease
11. The evaluation and treatment of adults with gastroesophageal reflux disease
12. Prevalence of gastrointestinal symptoms in the general population: A systematic review
13. The esophagus
14. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease
15. Epidemiology and natural history of gastro-oesophageal reflux disease
16. The relationship between stress and symptoms of gastroesophageal reflux: The influence of psychological factors
17. No relation between body mass and gastroesophageal reflux symptoms in a Swedish population based study
18. Review article: Is Helicobacter pylori status relevant in the management of GORD?
19. Helicobacter pylori infection and gastro-oesophageal reflux disease: Coincidence or association
20. The anti-reflux barrier and mechanisms of gastro-oesophageal reflux
21. The diagnosis and management of gastroesophageal reflux disease
22. Symptoms in gastro-oesophageal reflux disease
23. Prevalence of symptoms of dyspepsia in the community
24. The usefulness of a structured questionnaire in the assesment of symptomatic gastroesophageal reflux disease
25. Functional gastroduodenal disorders
26. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease The Practice Parameters Committee of American College of Gastroenterology
27. The role of endoscopy in the management of GERD: Guidelines for clinical application
28. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
29. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease
30. Empiric therapy for gastroesophageal reflux disease
31. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough
32. Lansoprazole treatment of patients with chronic idiopathic laryngitis: A placebo-controlled trial
33. Strategies for medical management of reflux disease
34. The preoperative evaluation of patients considered for laparoscopic antirefluxsurgery
35. Clinical esophageal pH recording: A technical review for practice guideline development
36. Barrett's esophagus: A prevalent, occult complication of gastroesophageal reflux disease
37. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?
38. Barrett's esophagus
39. Adenocarcinoma of the esophagus and gastric cardia: Is there progress in the face of increasing cancer incidence?
40. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
41. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia
42. Rising incidence of adenocarcinoma of the esophagus and gastric cardia
43. Adenocarcinoma of the esophagus: Risk factors and prevention
44. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis
45. Comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease
46. Double-blind controlled trial of betanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis
47. Managing heartburn at the "base" of the GERD "iceberg": Effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids
48. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease (Cochrane Review)
49. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn
50. An evaluation of increasing doses of ranitidine for treatment of heart-burn
51. Low-dose ranitidine for the relief of heartburn
52. Gastro-oesophageal reflux symptoms - Clinical findings and effect of ranitidine treatment
53. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
54. High -versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: A prospective, controlled trial
55. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis
56. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis
57. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - A placebo-controlled randomized trial
58. Esomeprazole 20 mg maintains symptoms control in endoscopy-negative gastroesophageal reflux disease: A controlled trial of "on-demand" therapy for 6 months
59. Symptomatic gastro-oesophageal reflux disease: Double blind controlled study of intermittent treatment with omprazole or ranitidine
60. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease
61. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease
62. Esomeprazole 40 mg and 20 mg is effectivein long-term management of endoscopy negative GORD. A placebo-controlled trial of "on-demand" therapy
63. Omeprazole 10 mg once daily, omeprazole 20 mg once daily or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms gastroesophageal reflux in general public
64. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining response
65. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
66. Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia
67. Oral pantoprazole for erosive esophagitis: A placebo-controlled, randomized clinical trial
68. Heartburn treatment in primary care: Randomised, double blind study for 8 weeks
69. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis
70. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oeso-phageal reflux disease
71. Pantoprazole versus omeprazole in the treatment of reflux esophagitis
72. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole
73. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial)
74. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oeso-phagitis patients: A randomized controlled trial
75. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
76. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - A prospective, randomized, multi-centre study
77. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: A double-blind, multicenter. European trial
78. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety
79. Efficacy and cost effectiveness of lansoprazole versus omeprazole in maintenance treatment of symptomatic gastroeso-phageal reflux disease
80. Erosive oeso-phagitis: Outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo
81. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis
82. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: Short and long-term treatment
83. Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease
84. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease
85. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy
86. Effective maintenance treatment of reflux eso-phagitis with low-dose lansoprazole
87. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease
88. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis
89. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dispepsia in general practice
90. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease - A prospective, controlled trial
91. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease
92. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia
93. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: A randomized, double-blind, parallel, and multicentre study
94. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: A double-blind, randomized clinical trial
95. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis
96. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy
97. A comparison of five maintenance therapies for reflux esophagitis
98. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease
99. Metoclopramide in gastroe-sophageal reflux disease: Rationale for its use and results of a double-blind trial
100. FDA warns about heartburn drug
101. The floppy Nissen fundoplication. Effective long-term control of pathologic reflux
102. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients
103. Long-term results of Nissen fundoplication in reflux esophagitis without strictures. Clinical, endoscopic, and pH-metric evaluation
104. Value of Nissen fundoplication in patients with gastro-oesophageal reflux judged by long-term symptom control
105. Long-term efficacy of 180° anterior fundoplication for severe gastro-oesophageal reflux disease
106. Prospective study of symptoms and gastro-oesophageal reflux 10 years after posterior partial fundoplication
107. Digestive system disorders: Gastroesophageal reflux disease
108. Randomized clinical trial of laparoscopic versus open fundoplication: Blind evaluation of recovery and discharge period
109. Comparison of laparoscopic and open Nissen fundoplication 2 years after operation. A prospective randomized trial
110. Long-term management of gastroóesophageal reflux disease with omeprazole or open antireflux surgery: Results of a prospective, randomized clinical trial
111. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease
112. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial
113. Surgical therapy for reflux disease
114. Fatal and life-threatening complications in antireflux surgery: Analysis of 5, 502 operations
115. GERD in primary care. Comparison and development of European guidelines on gastroesophageal reflux disease
116. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease
117. French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease. Diagnosis and treatment report of a meeting held in Paris, France on 21-22 January 1999. The jury of the consensus conference
118. The second Canadian gastroesophageal reflux disease consensus: Moving forward to new concepts
119. The 1996 Canadian outlook on gastroesophageal reflux disease. Consensus Conference. Ottawa, Ontario, June 1996
120. Management of gastro-oesophageal reflux disease in general practice